The U.S. House of Representatives is considering a bill that would require cosmetics containing talc marketed to children to provide a warning label that the products may be contaminated with asbestos.
The Children’s Product Warning Label Act, introduced by Representatives Debbie Dingell (D–Michigan) and Jan Schakowsky (D–Illinois), was introduced amid heightened scrutiny of the presence of asbestos in products.
A House of Representatives hearing last week focused on a recent Food and Drug Administration investigation into its presence in certain talc-based makeup products sold at two major national retailers, Claire’s and Justice. The concerns continue as to the alleged asbestos contamination in Johnson & Johnson’s talcum baby powder.
The recently introduced legislation would require children’s cosmetics to bear a warning label that the product has not been evaluated for such contamination unless the manufacturer has demonstrated to the FDA that the product has been sourced from an asbestos-free mine.
Rep. Schakowsky characterized
the bill as “an important step towards eliminating toxic substances from beauty and personal care products and to give the U.S. FDA the authority it needs to keep Americans safe.”
“I will continue to fight for full disclosure of the many chemicals in our products, including dangerous carcinogens like asbestos,” Schakowsky added.
Separate legislation will also be introduced to strengthen the FDA’s authority over cosmetics. Current law has not been amended significantly since 1938.
The Reinstein Ban Asbestos Now Act has been reintroduced in both the Senate and the House.
And both the Senate and House have seen the reintroduction of the Alan The bill seeks to amend TSCA to ban the manufacturing, processing, use, and distribution in commerce of asbestos and any mixture or articles containing it. with limited exemptions. The measure would allow limited exemptions to the use of the substance.
Asbestos is one of the first ten chemicals subject to a risk evaluation under the amended TSCA. A draft assessment to determine whether the substance poses an unreasonable risk to human health or the environment, under its conditions of use, is expected in the near future.